BMY241206C48000
- 11.90
- 0.000.00%
ブリストル・マイヤーズのニュース一覧
PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy
AI Proteins Announces Research Collaboration and Option Agreement With Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued up to $400M
Bristol-Myers Squibb Company (BMY): Close to Becoming a Dividend Aristocrat
Ovarian Cancer Therapeutics Business Research Report 2024-2030, Profiles of 12 Players Including Amgen, AstraZeneca, and Bristol-Myers Squibb Company
Is Bristol-Myers Squibb Stock a Millionaire Maker?
Catalyst Watch: November Jobs, OPEC+ Meeting, Marvell, Salesforce Earnings
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Bristol Myers Squibb to Participate in Citi's 2024 Global Healthcare Conference
Bristol-Myers Squibb Hits 14-month High
Merck Phase 3 Study of Winrevair in PAH Meets Primary Endpoint
Bernstein Adjusts Price Target on Bristol-Myers Squibb to $62 From $56, Keeps Market Perform Rating
Pension Doubles Its Palantir Stake and Buys Up Intel and CVS. -- Barron's
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC
Replimune Climbs After Updates on Lead Drug
Optimism Over Global Healthcare Sector Rises: Jefferies
Investing in Bristol-Myers Squibb (NYSE:BMY) a Year Ago Would Have Delivered You a 24% Gain
BRISTOL-MYERS SQUIBB CANADA WINS THE 2024 PRIX GALIEN INNOVATIVE PRODUCT AWARD
Bristol-Myers Squibb Company (BMY) Jefferies London Healthcare Conference (Transcript)
トゥルイスト・ファイナンシャルはブリストル・マイヤーズ(BMY.US)のレーティングを強気に据え置き
トゥルイスト・ファイナンシャルのアナリストSrikripa Devarakondaは$Bristol-Myers Squibb(BMY.US)$のレーティングを強気に据え置き。TipRanksのデータによると、このアナリストの最近1年間の的中率は50.3%、平均リターンは13.1%である。注 TipRanksは、金融アナリストの分析データと、アナリストの的中率および平均リターンに関する情報を提供し
Bristol Myers Squibb's Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms